EUVIMEDEUVIMED entdecken
Crossref

Pracinostat inhibits the nefarious biological behavior of pancreatic cancer by targeting the miR-381–3p/MDM2 axis to activate the p53 signaling pathway

Dongyun Cun, Feng Liu, DaGuang Tian, TieHan Li, ZhaoHao Guo, Peng Chen

Pathology - Research and Practice · 2025-10 · 274 · 156186

DOI: 10.1016/j.prp.2025.156186 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pathology - Research and Practice, 2025-10. Verfasst von Dongyun Cun und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatobiliary and Pancreatic Surgery, Second Affiliated Hospital of Kunming Medical University, China. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Signal Transduction, Tumor Suppressor Protein p53, MicroRNAs. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: Yunnan Provincial Science and Technology Department.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: Pancreatic cancer is one of the most aggressive malignant tumors in humans, with poor prognosis. The acetylase tumor inhibitor (Pracinostat) has been shown to suppress the growth of various tumors. This study aimed to investigate the effects of Pracinostat on the pancreatic cancer cell line BxPC3 and to explore the underlying molecular mechanisms through both in vivo and in vitro experiments. METHODS: BxPC3 cells were treated with Pracinostat, and cell viability was assessed by CCK-8 assay; the differentially expressed miRNAs in cells before and after pracinostat treatment were screened by high-throughput sequencing, and miR-381-3p was selected as the target gene; the targeting relationship between miR-381-3p and MDM2 was verified by double luciferase reporter gene; the relationship between miR-381-3p, MDM2 and P53 signaling pathways was verified by immunoprecipitation, Western blot and other experiments. Pancreatic tumor models were established in BALB/c nude mice to study the role of pracinostat in vivo. RESULTS: Pracinostat upregulated the expression of miR-381-3p and p53, while downregulating MDM2 expression. It also inhibited the proliferation and migration of pancreatic cancer cells and promoted apoptosis. Treatment with a miR-381-3p inhibitor reversed the effects of Pracinostat. In addition, MDM2 was found to promote the ubiquitination and degradation of p53 via the ubiquitin-proteasome pathway. In vivo experiments confirmed that Pracinostat inhibited tumor growth in nude mice. CONCLUSION: pracinostat activates the p53 signaling pathway by targeting the miR-381-3p/MDM2 axis, thereby inhibiting the proliferation of pancreatic cancer cells. These findings provide novel insights and potential therapeutic strategies for pancreatic cancer, and may also provide a reference for the treatment of other malignancies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pancreatic NeoplasmsSignal TransductionTumor Suppressor Protein p53MicroRNAsProto-Oncogene Proteins c-mdm2Histone Deacetylase InhibitorsBenzimidazolesHumansCell Line, TumorGene Expression Regulation, NeoplasticApoptosisCell ProliferationCell MovementUbiquitinationAnimalsMiceMice, NudeMaleAntineoplastic Agents

Stichwörter der Autor:innen

Degradation of p53 ubiquitinationMDM2MiR-381–3pPancreatic cancerPracinostat

Substanzen

SB939 compoundBenzimidazolesTP53 protein, humanMIRN381 microRNA, humanMDM2 protein, humanTumor Suppressor Protein p53MicroRNAsProto-Oncogene Proteins c-mdm2Histone Deacetylase InhibitorsAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Hepatobiliary and Pancreatic Surgery, Second Affiliated Hospital of Kunming Medical University, China.
  • Department of Hepatobiliary and Pancreatic Surgery, Kunming Medical University, China.
  • Department of Hepatobiliary and Pancreatic Surgery, Second Affiliated Hospital of Kunming Medical University, China. Electronic address: chenpeng2024@126.com.

Förderung

  • Yunnan Provincial Science and Technology Department

Zitieren

APA

Cun, D., Liu, F., Tian, D., Li, T., Guo, Z., & Chen, P. (2025). Pracinostat inhibits the nefarious biological behavior of pancreatic cancer by targeting the miR-381–3p/MDM2 axis to activate the p53 signaling pathway. Pathology - Research and Practice, 274, 156186. https://doi.org/10.1016/j.prp.2025.156186

Vancouver

Cun D, Liu F, Tian D, Li T, Guo Z, Chen P. Pracinostat inhibits the nefarious biological behavior of pancreatic cancer by targeting the miR-381–3p/MDM2 axis to activate the p53 signaling pathway. Pathology - Research and Practice. 2025;274:156186. doi:10.1016/j.prp.2025.156186

BibTeX
@article{Cun2025,
  author = {Cun, Dongyun and Liu, Feng and Tian, DaGuang and Li, TieHan and Guo, ZhaoHao and Chen, Peng},
  title = {Pracinostat inhibits the nefarious biological behavior of pancreatic cancer by targeting the miR-381–3p/MDM2 axis to activate the p53 signaling pathway},
  journal = {Pathology - Research and Practice},
  year = {2025},
  volume = {274},
  pages = {156186},
  doi = {10.1016/j.prp.2025.156186}
}
Kostenlos starten →